RLAY

Relay Therapeutics Stock Analysis

AI Rating

Low
  • Quality3/10
  • Growth↑ 5/10
  • Value↓ 0/10
Relay Therapeutics sales and earnings growth
RLAY Growth
Neutral
  • Revenue Y/Y↑ 53.44%
  • EPS Y/Y↑ 31.78%
  • FCF Y/Y↑ 6.08%
Relay Therapeutics gross and profit margin trends
RLAY Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -1800.60%
  • ROIC 5Y↓ -44.08%
Relay Therapeutics net debt vs free cash flow
RLAY Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Relay Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗